How big is IDEAYA Biosciences, Inc.?

As of Jun 18, IDEAYA Biosciences, Inc. has a market capitalization of 1,919.80 million, with net sales of 7.00 million and a net profit of -307.08 million over the latest four quarters. The company reported shareholder's funds of 1,059.15 million and total assets of 1,124.09 million as of Dec 24.

Market Cap: As of Jun 18, IDEAYA Biosciences, Inc. has a market capitalization of 1,919.80 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, IDEAYA Biosciences, Inc. reported net sales of 7.00 million and a net profit of -307.08 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,059.15 million and total assets of 1,124.09 million.

What does IDEAYA Biosciences, Inc. do?

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company that develops targeted therapeutics. As of March 2025, it has a market cap of approximately $1.92 billion and reported a net profit loss of $72 million.

Overview: <BR>IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company in the Pharmaceuticals & Biotechnology industry, specializing in the discovery and development of targeted therapeutics.<BR><BR>Financial Snapshot: <BR>Net Profit: -72 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,919.80 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.68 <BR>Return on Equity: -29.98% <BR>Price to Book: 1.87<BR><BR>Contact Details: <BR>Address: 7000 Shoreline Ct Ste 350, SOUTH SAN FRANCISCO CA: 94080-7604 <BR>Tel: 1 650 4436209 <BR>Fax: 1 302 6555049 <BR>Website: https://www.ideayabio.com/

Should I buy, sell or hold IDEAYA Biosciences, Inc.?

Who are in the management team of IDEAYA Biosciences, Inc.?

As of March 2022, the management team of IDEAYA Biosciences, Inc. includes Mr. Tim Shannon as Independent Chairman and Mr. Yujiro Hata as President and CEO, along with several independent directors on the Board.

As of March 2022, the management team of IDEAYA Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Tim Shannon, Independent Chairman of the Board<BR>- Mr. Yujiro Hata, President, Chief Executive Officer, and Director<BR><BR>Additionally, the Board of Directors consists of several independent directors, including Mr. Garret Hampton, Mr. Scott Morrison, Dr. Terry Rosen, Hr. Thilo Schroeder, and Dr. Jeffrey Stein.

Is IDEAYA Biosciences, Inc. overvalued or undervalued?

As of November 12, 2020, IDEAYA Biosciences, Inc. is considered a risky investment due to its high valuation metrics and recent underperformance compared to peers and the S&P 500.

As of 12 November 2020, the valuation grade for IDEAYA Biosciences, Inc. moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 1.86, an EV to EBITDA of -3.40, and a negative ROCE of -108.56%. In comparison to its peers, IDEAYA's EV to EBITDA ratio is significantly worse than Madrigal Pharmaceuticals, Inc. at -30.5845 and Ultragenyx Pharmaceutical, Inc. at -7.2361, both of which also fall under the risky category.<BR><BR>While IDEAYA has shown strong returns over the longer term, with a 134.95% return over three years, its recent performance has lagged behind the S&P 500, particularly with a -24.55% return over the past year compared to the index's 17.14%. This underperformance, combined with its high valuation ratios relative to peers, suggests that IDEAYA may not be a favorable investment at this time.

Is IDEAYA Biosciences, Inc. technically bullish or bearish?

As of October 3, 2025, IDEAYA Biosciences, Inc. shows a bullish trend supported by strong daily moving averages and weekly MACD, despite mixed signals from monthly indicators and underperformance compared to the S&P 500 over the past month and year.

As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong daily moving average signal and a weekly MACD indicating bullish momentum. However, the monthly MACD is only mildly bullish, and the KST shows a bearish signal on that timeframe. The Bollinger Bands present a mixed view, being mildly bullish weekly but mildly bearish monthly. The stock has underperformed the S&P 500 over the past month and year, returning 1.22% compared to the S&P's 4.15% for the month and -8.27% against the S&P's 17.82% for the year, while it has outperformed over the 3-year and 5-year periods. Overall, the strength of the bullish trend is supported by the daily moving averages and weekly MACD, despite some mixed signals from other indicators.